These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16123131)

  • 1. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
    Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted proapoptotic anticancer drug delivery system.
    Chandna P; Saad M; Wang Y; Ber E; Khandare J; Vetcher AA; Soldatenkov VA; Minko T
    Mol Pharm; 2007; 4(5):668-78. PubMed ID: 17685579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.
    Shah V; Taratula O; Garbuzenko OB; Taratula OR; Rodriguez-Rodriguez L; Minko T
    Clin Cancer Res; 2013 Nov; 19(22):6193-204. PubMed ID: 24036854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.
    Kheirandish MH; Jaliani HZ; Rahmani B; Nikukar H
    Toxicon; 2019 Jun; 164():82-86. PubMed ID: 30991063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer.
    Obayemi JD; Salifu AA; Eluu SC; Uzonwanne VO; Jusu SM; Nwazojie CC; Onyekanne CE; Ojelabi O; Payne L; Moore CM; King JA; Soboyejo WO
    Sci Rep; 2020 May; 10(1):8212. PubMed ID: 32427904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Based Nanocarrier by Targeting with LHRH Peptide: A Promising Approach for Prostate Cancer Radio-Imaging and Therapy.
    De K; Tanbir SKE; Sinha S; Mukhopadhyay S
    Mol Pharm; 2024 Aug; 21(8):4128-4146. PubMed ID: 38920398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LHRH-Targeted Drug Delivery Systems for Cancer Therapy.
    Li X; Taratula O; Taratula O; Schumann C; Minko T
    Mini Rev Med Chem; 2017; 17(3):258-267. PubMed ID: 27739358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
    Saad M; Garbuzenko OB; Ber E; Chandna P; Khandare JJ; Pozharov VP; Minko T
    J Control Release; 2008 Sep; 130(2):107-14. PubMed ID: 18582982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted proapoptotic LHRH-BH3 peptide.
    Dharap SS; Minko T
    Pharm Res; 2003 Jun; 20(6):889-96. PubMed ID: 12817893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
    Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
    Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
    Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
    Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
    He Y; Zhang L; Song C
    Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers.
    Ghanghoria R; Kesharwani P; Tekade RK; Jain NK
    J Control Release; 2018 Jan; 269():277-301. PubMed ID: 27840168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.
    Aggarwal S; Ndinguri MW; Solipuram R; Wakamatsu N; Hammer RP; Ingram D; Hansel W
    Int J Cancer; 2011 Oct; 129(7):1611-23. PubMed ID: 21484797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
    Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.
    Dharap SS; Qiu B; Williams GC; Sinko P; Stein S; Minko T
    J Control Release; 2003 Aug; 91(1-2):61-73. PubMed ID: 12932638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
    Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
    Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.